# Argipressin's Influence on Blood Loss During Hepatic Resection

> **NCT05293041** · PHASE4 · COMPLETED · sponsor: **Kristina Svennerholm** · enrollment: 248 (actual)

## Conditions studied

- Colon Cancer Liver Metastasis
- Inflammatory Response
- Vasopressin Causing Adverse Effects in Therapeutic Use

## Interventions

- **DRUG:** Argipressin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05293041
- **Lead sponsor:** Kristina Svennerholm
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-27
- **Primary completion:** 2024-12-06
- **Final completion:** 2025-02-17
- **Target enrollment:** 248 (ACTUAL)
- **Last updated:** 2025-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05293041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05293041, "Argipressin's Influence on Blood Loss During Hepatic Resection". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05293041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*